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NeuroprosthesisControlled release coatings were developed for neuroprostheses with the aim of combating the tissue
reaction following implantation in the brain. The coatings consist of poly(propylene sulﬁde) drug-eluting
nanoparticles embedded in a poly(ethylene oxide) matrix. The nanoparticles are loaded with dexametha-
sone, an anti-inﬂammatory drug known to have an effect on the cells activated during the damage caused by
implantation. The nanoparticles are not affected by the coating process and the drug remains bioactive after
it is released. The coating was applied to microfabricated cortical neuroprostheses consisting of platinum and
polyimide. Coated drug-eluting devices were implanted in the cortex of rats. After implantation the matrix
dissolves, exposing the electrode surfaces, while the nanoparticles remain in the vicinity of the tissue–
implant interface. Using electrical impedance spectroscopy and comparative histology, a long-term decrease
in the tissue response in comparison to control devices was observed. These coatings can therefore be used
to increase the reliability and long-term efﬁcacy of neuroprostheses.+41 21 693 59 50.
nzini).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Microelectrodes implanted in nervous tissue can be used to
stimulate or record neural activity and may one day reproduce neural
functions lost to trauma or disease [1]. A limiting factor with
microelectrodes chronically implanted in the brain is their loss of
electrical contact with neural tissue due to the post-implantation
inﬂammatory reaction, gliosis, and ﬁbrosis [2–4]. Glial cells rapidly
migrate to the implantation site surrounding the device, thus
physically separating the microelectrode sites from the neurons
they are meant to be recording from or stimulating. The efﬁciency of
the implanted device decreases steadily with time. After approxi-
mately two to threeweeks, the inﬂammatory response has reached its
peak, electrical impedance measurements have stabilized at their
maximum [5], and the number of chronically recorded single units has
reached its minimum [6]. If microelectrode arrays are to be effective in
neural stimulation and recording, the tissue response must be
reduced or prevented in order to maintain stable microelectrode–
tissue contact and neuroprostheses functionality.
Several approaches to limiting this tissue reaction have been
reported, including surface modiﬁcation to prevent cell adhesion [7],localized release of alpha-melanocyte stimulating hormone (α-MSH)
[8] or nerve growth factor β [9], and dexamethasone injection [10].
The approach presented here involves coating microelectrode arrays
with bio-resorbable drug-eluting material. We hypothesized that
highly localized delivery of an anti-inﬂammatory drug around the
implantation site would reduce the tissue response to implantation
and improve recording and stimulation characteristics. The goal of
this work was to determine the efﬁcacy of these drug-eluting coatings
to combat the inﬂammatory response to implantation.
Novel nanoparticle-embedded coatings were designed and eval-
uated for the controlled release of dexamethasone, which has been
shown to be effective in reducing the brain response to implantable
devices [10,11]. Its release from poly(lactic-co-glycolic acid) (PLGA)
nanoparticles was shown by Kim and Martin [12] using rigid silicon
probes, however in this experiment the neuroprostheses were
polymeric, resulting in less post-implantation injury and eventually
a more straightforward translation into clinical use.
Dexamethasone was loaded into poly(propylene sulﬁde) (PPS)
nanoparticles which were then incorporated into poly(ethylene
oxide) (PEO), a bio-resorbable polymer, and applied as a coating to
the neuroprosthesis. The PEO is meant to dissolve soon after
implantation, thereby releasing the drug-loaded nanoparticles and
exposing the electrode sites. The nanoparticles are large enough to not
diffuse from the surface of the implanted device and can maintain
sustained release at the implantation site. The nanoparticles were
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were not damaged using scanning electron microscopy (SEM) and in
vitro release rates were obtained. In vivo efﬁcacy in the brain was
evaluated using two different methods in the rat model. The ﬁrst was
by measuring the electrical characteristics of the tissue reaction using
electrical impedance spectroscopy. The second was with immuno-
ﬂuorescence which gives qualitative insight into the cell morphology
around the device.
We demonstrate with this study that the highly localized release of
dexamethasone around the neuroprosthesis indeed reduces the long-
term tissue reaction. In stimulation applications of neuroprostheses, a
reduction in the tissue reaction will enable more efﬁcient charge
transfer during neural stimulation, reducing the current required and
preventing toxic electrochemical reactions at the metal microelec-
trode surface [13]. In recording applications of neuroprostheses, the
signal-to-noise ratio may be improved if the degree of the tissue
reaction is reduced [14,15]. These are important factors for the
continued use of microelectrode based neuroprostheses in research,
and may accelerate the translation of this technology into clinic
applications.
2. Materials and methods
2.1. Microelectrode array fabrication
Several materials and processes to make neuroprostheses using
thin ﬁlm technology have been shown [16–18]. The devices presented
here are based on polyimide-platinummicrofabrication, for which the
full fabrication method has been previously published [19,20]. These
devices have also been demonstrated in vivo for both acute and
chronic measurements [20,21]. Fig. 1A) demonstrates the device used
in these experiments, while Fig. 1B) shows a close-up of the tip
dimensions. The tip was composed of four microelectrodes of 50 µm
diameter with spacing of 150 µm or 300 µm. The device thickness was
60 µm.
Each device consisted of two probes, one for each hemisphere of
the brain, totaling 8 microelectrodes per animal. One probe was
coated with the drug-eluting material, while the other probe was
coated with the non-drug-loaded coating and served as the control.
The stiffness of ﬂexible devicesmay be an issue during implantation in
deeper areas of the brain. The devices are ﬂexible, but stiff enough [22]
to penetrate the cortical tissue by more than 1 mm.Fig. 1. A) The implantable device demonstrating the left and right hemisphere probes,
and the electrical connector which remains extracorporeal. The scale is in centimeters.
B) The design of the probe tip demonstrating microelectrode sizes and spacing.
Adapted from Ref. [5].Separate microelectrode arrays for histological evaluation were
fabricated using the same process described above, but with slightly
different dimensions such that the short histology microelectrode
array completely surpassed the dura mater to prevent it from
adhering to the inside of the skull.
2.2. Nanoparticle–PEO coating synthesis
2.2.1. Nanoparticle preparation
We follow the procedure for synthesizing nanoparticles described
elsewhere [23,24]. For further applications of the nanoparticles, the
reader is directed to Reddy et al. [25,26]. All solvents and reagents
were purchased from Sigma-Aldrich (Buchs, Switzerland). Double-
distilled and puriﬁed water was deoxygenated by bubbling nitrogen
gas in a slight vacuum environment and stirring at 1000 rpm for 1 h.
While ﬂooding the beaker with nitrogen gas, 35 mg of Pluronic F-
127® was added and stirred at 1000 rpm for 1 h until completely
dissolved. 400 µL of propylene sulﬁde was added to the solution
continuously under nitrogen purge and was allowed to mix for 5 min
before adding the initiator solution. The initiator consists of
unprotected pentaerythritol tetrathioester and was prepared as
described elsewhere [27]. Sodium methoxide in methanol was used
to activate the SH end groups (i.e. deprotect) of the pentaerythritol
tetrathioester and initiate polymerization of the propylene sulﬁde
monomer. 200 µL of 0.5 M sodium methoxide was added to the
pentaerythritol tetrathioester in a nitrogen gas environment. The
initiator solution was then added to the monomer and Pluronic®
surfactant solution and stirred for 3 min in a constant nitrogen
environment. 60 µL of the organic base 1,8-diazabicyclo [5.4.0] undec-
7-ene was added to the solution. This reagent is highly hydrophobic
and is believed to improve particle formation. The solution was
allowed to stir overnight and upon exposure to air the PPS becomes
oxidized, resulting in disulﬁde formation, and thus a crosslinked PPS
core. The nanoparticle solution was then puriﬁed by dialysis in
ultrapure Millipore water with a 100 kDa dialysis membrane for
3 days with 2 buffer changes per day, ensuring that the solution is void
of unreacted Pluronic®, PPS and reagents. Once formed, nanoparticles
can be kept in solution for several months at 4 °C without apparent
degradation.
2.2.2. Dexamethasone loading
To deliver therapeutic drug amounts, the nanoparticles must be
efﬁciently loaded to ensure high drug concentration and this was
achieved by a cosolvent-evaporation in water technique [28]. 5 mg of
dexamethasone was added to 400 µL of methanol and stirred until
dissolved. 1 mL of the nanoparticle solution described above was
added to the dexamethasone–methanol solution and the mixture was
stirred for 8 h covered only by a particle free tissue to allow the
solvent to evaporate. During the cosolvent (methanol) evaporation,
the hydrophobic dexamethasone molecule will permeate the Pluro-
nic® corona of the nanoparticles and remain in the hydrophobic PPS
core. The solution was then puriﬁed by centrifugation at 11 krpm
(6800 g) for 10 min. After centrifugation, a precipitate of unloaded
dexamethasone was visible at the bottom of the vial. The weight of
this remaining dexamethasone represents the unloaded drug. The
supernatant consists of the dexamethasone-loaded nanoparticles and
was removed for sizing experiments and for coating preparation. The
nanoparticle solution was sterile ﬁltered through a 0.22 µm ﬁlter.
2.2.3. Nanoparticle incorporation with PEO
The nanoparticle–dexamethasone solution was suspended in a
PEO matrix, and then applied to the neural probes using a dip and
reﬂow method. This forms uniform ﬁlms around the probe.
The PEO solution was prepared by dissolving 200 mg of
1,000,000 g/mol molecular weight PEO (Sigma-Aldrich, Switzerland)
in 8 mL of puriﬁed water. A 1 mL suspension of dexamethasone-
Fig. 2. A coronal slice demonstrating microelectrode array placement in the primary
motor cortex (M1).
Adapted from Ref. [29].
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solution and stirred in order to disperse the nanoparticles. A neural
probe was inserted into the viscous solution and quickly pulled out.
The PEO–nanoparticle suspension was allowed to air dry, forming a
non-uniform layer around the neural probe. The coated probe was
then placed in an oven at 60 °C for 2 min and the PEO–nanoparticle
suspensionwas allowed to reﬂow around the probe forming a smooth
and uniform coating around the device. The coated neural probe can
then be stored at 5 °C for several hours before implantation. Control
probes were prepared in precisely the same manner, except the
nanoparticles used in the preparation had not been loaded with
dexamethasone.
2.2.4. Nanoparticle characterization
The produced nanoparticles were characterized for their size,
robustness after the coating process, release rate, and retained
bioactivity after release. A dynamic light scattering instrument
(Zetasizer Nano Series, Malvern Instruments Ltd, UK) was used to
measure a sample of the solution to determine the average
nanoparticle diameter before loading of dexamethasone.
Nanoparticles were imaged in order to conﬁrm correct nanopar-
ticle formation and retained structural integrity after embedment
within the PEO matrix and subsequent re-hydration. Nanoparticles
were imaged using a modern electron microscopy technique which
permits study of materials in atmospheric and aqueous solutions
within a scanning electron microscope (SEM). This technique differs
from so-called “environmental SEM” because it can be performed in a
conventional SEM using QX-102 WETSEM® capsules purchased from
Quantomix Corporation (Rehovot, Israel). Two nanoparticle solution
samples were prepared and placed in two such capsules. The ﬁrst
sample consisted of nanoparticles after dexamethasone loading. The
second sample consisted of loaded nanoparticles that had been
embedded in the PEO matrix, followed by dehydration of the PEO
matrix in the same manner used during coating, and ﬁnally re-
hydrated. The second sample closely resembles the coating process
and evaluates the robustness of the nanoparticles.
The release rate of the nanoparticles was determined using an in
vitro dialysis procedurewhich helpedmodel in vivo conditions. A 1 mL
sample of loaded nanoparticle solution was placed in a cellulose
dialysis membrane with a nominal molecular weight cutoff of 12 kDa
(Cole Parmer, IL, USA). The membrane was placed in a 1 L beaker of
puriﬁed water for 10 days. Daily samples of 100 µL were removed
from the membrane, and immediately freeze dried. The daily samples
demonstrate a decreasing concentration of dexamethasone, as it
slowly diffuses from the nanoparticles and out of the dialysis
membrane.
The freeze dried samples representing daily dexamethasone
concentration were then dissolved in 100 µL of tetrahydrofuran
(THF) (Sigma-Aldrich, Switzerland). Gel permeation chromatography
was used to determine the exact concentration of bioactive dexa-
methasone in these samples in comparison to standard concentration
measurements.
Samples (in THF) were injected into three serial Waters Styragel
HR columns (Waters Corp, Delaware). A 1 mL/min THF mobile phase
set at 40 °C allowed the detection of the polymer using a differential
refractometer detector (model 410, Waters) or a UV detector
(photodiode array detector, Waters Corp. model 996).
2.3. Implantation
Animal care and experimental procedures were performed in
accordance with the Swiss legislation on animal protection and
experimentation. Six adult female RCS rats were anesthetized with
xylasine (Narcoxyl® 2 at 10 mg/kg) and ketamine (Ketaminol® 10 at
75 mg/kg). Subjects were implanted using a stereotaxic frame in the
primary motor cortex. Four subjects received devices for impedancemeasurements, and two subjects received devices for histology. Each
subject had one hemisphere implantedwith a drug-eluting probe, and
the opposite hemisphere with a control probe. The four subjects used
for impedance measurements had four microelectrodes per hemi-
sphere, resulting in 32 microelectrode sites that were measured
during the experiment.
Stereotactic coordinates were set to +1.5 anterior, +2.5 mm and
−2.5 mm lateral from bregma, toothbar was −3.3 mm [29]. Fig. 2
demonstrates a coronal image of the device placement. An incision
was made to expose the skull and six 2 mm diameter craniotomies
were performed remove the skull and pierce the dura mater. Once the
device was implanted it was stabilized using dental acrylic. The skin
was sutured and animals recovered in a warm environment.
Two of the craniotomies were used as device implantation sites
and the remaining four were used for self-tapping stainless steel
screws, which served to stabilize the implant using dental acrylic after
implantation. The two rear screws also served as the signal ground
and must be in contact with the cortex. Animals were kept for a total
of 46 days.2.4. In vivo impedance measurements
Experimental measurements of tissue reaction properties were
obtained for each animal subject during the study. Subjects were
measured while temporarily anesthetized daily for the ﬁrst two
weeks and every three days until animal sacriﬁce. Electrical
impedance spectroscopy measurements were performed with an
Agilent 4294A impedance analyzer connected to a routing circuit
which directs the impedance measurement signal to each microelec-
trode site. The impedance of each individual microelectrode was
recorded using proprietary MATLAB® software. A frequency sweep
from 100 Hz to 1 MHz was performed at 100 mV amplitude, thereby
sufﬁciently covering the bandwidth of electrophysiological interest
and identifying important material properties.
The experiments and model described by Mercanzini et al. [5]
demonstrate how the exact resistance of the tissue reaction can be
determined using the technique of Peak Resistance Frequency
analysis. This method is more powerful than conventional impedance
measurements at 1 kHz because it isolates and identiﬁes the
resistance of the tissue surrounding the electrode. The reader is
referred to this reference for a more detailed explanation of the Peak
Resistance Frequency.
Fig. 4. Median nanoparticle size distribution as determined using dynamic light
scattering (note that x-axis is a log scale). Before embedding in the PEO matrix the
nanoparticles demonstrate a median diameter of 100 nm (dashed line). After
embedding in the PEO matrix and subsequent, dehydration, and re-hydration, the
nanoparticles demonstrate a median diameter of 800 nm (solid line) indicative of
aggregation.
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Separate implants were made for histology that did not have
electrical contacts leading outside of the animal in order to facilitate
microtome sections of the brain with the microelectrode array
present. This does not permit a direct quantitative correlation
between histology and electrophysiological data, but further devel-
opment on histological techniques may permit such an experiment.
At 1 and 3 week time points, rat brains were transcardially
perfused with a 4% paraformaldehyde-containing saline solution. A
parafﬁn microtome (Microm HM325, MicromMicrotech, France) was
used to slice the tissue with electrodes in place in 25 µm slices. Slices
were de-paraﬁnized by heating to 60 °C for 20 min and immediately
rinsing in toluene twice for 5 min each. The slices were then rinsed
with ethyl alcohol at concentrations of 100%, 95%, 80% and 65% for
5 min at each concentration then washed in DI water. The slices were
then incubated in 10 mM citric acid (pH 6) at 90 °C for 20 min and
allowed to cool (antigen retrieval) and then washed in PBS twice for
5 min each. Slices were incubated at room temperature for one hr in a
solution consisting of 1% BSA, 2% donkey serum and 0.1% Triton-X in
PBS. Slices were then incubated for 12 h at 4 °C with the primary
antibodies: 0.5 µL/mL rabbit anti-Iba1 (Wako, IG Instrument, Zurich,
Switzerland) was the microglia marker and 1.25 µL/mL mouse anti-
glial ﬁbrillary acidic protein (GFAP; Dako, Sigma-Aldrich, Buchs,
Switzerland) was the astrocyte marker. After washing three times in
PBS for 5 min each, the slides were incubated at room temperature in
the secondary antibodies: Cy3 donkey anti-mouse 1.7 µL/mL and
Alexa 488 donkey anti-rabbit 1 µL/mL. The slides were washed three
times in PBS for 5 min each and incubated in 4′,6-diamidino-2-Fig. 3. A neural probe tip before coating (top image) and after the coating process
(bottom image). The scale bar applies to both images. Coating thickness was also
determined using electron microscopy to be 30 µm. Dimensions are given in Fig. 1.phenylindole (DAPI), a nuclei marker for all cells, at a concentration of
1 µL/mL for 15 min. The slides were washed twice for 5 min each in
PBS and bonded with cover slips using water-based glue.3. Results
3.1. Nanoparticle–PEO coating synthesis
Fig. 3 demonstrates a neural probe tip before and after coating. The
average dimensions of the coating are 230 µm wide, 30 µm thick, and
approximately 1000 µm in length. The coating is present on both sides
of the implant giving a ﬁnal coating volume of ∼15 nL.Fig. 5. WETSEM® images of PPS nanoparticles. A) The loaded nanoparticles appear as
white colored spheres, demonstrating diameters in range of 80–100 nm as expected
from the DLS measurements. B) The nanoparticles following the steps of embedded in
the PEO matrix, dehydration, and re-hydration. The nanoparticles became signiﬁcantly
larger but retained their dispersed structure.
Fig. 6. Percent release rate of dexamethasone-loaded nanoparticles. Complete drug
release was achieved after 9 days.
Fig. 8. Histological results comparing control and drug-loaded nanoparticle devices.
DAPI staining is for all cell nuclei, GFAP stains for astrocytes, IBA is for reactive
microglia. After 1 week there is a clear difference between the tissue reactions that have
formed around the control and drug-eluting probe. After 3 weeks bioimpedance
measurements demonstrate a stabilization of the tissue reaction, and this is supported
through histology. The reaction for drug-eluting probes is limited compared to the
control probes. A lower density of astrocytes is apparent. (Note: The slide which
displays the loaded week 3 sample has the remains of an embedded probe within).
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depicted in Fig. 4 before and after integration within the PEO matrix.
An average diameter of 100 nm is measured for the nanoparticles
before integration. After integration and subsequent dissolution, the
nanoparticles had an apparent increase in diameter to 800 nm on
average. This does not suggest an increase in the size of the PPS core,
but may be due to long PEO chains wrapping around its surface, in
addition to possible aggregation of several particles. However, this
does not affect the capability of the particles to retain or release the
loaded hydrophobic molecule as demonstrated by the release
experiments.
Imaging the nanoparticles using electron microscopy demonstrat-
ed that they retained a spherical shape after the coating and release
process. Fig. 5A) demonstrates the nanoparticles immediately after
loading with dexamethasone. Fig. 5B) demonstrates the nanoparticles
after re-hydration and release from the PEO matrix. They have
increased noticeably in size, which is in agreement with DLS
measurements.
The dexamethasone was loaded into the nanoparticles with a
maximum encapsulation efﬁciency of 15% w/w. The release rate over
9 days is depicted in Fig. 6. Data was ﬁtted to a quadratic curve to
guide the eye but is not meant to model release rate. A rapid release
up to 40% of the dexamethasone content was seen in the ﬁrst day, and
then a steady release continued until dexamethasone traces are no
longer detected.
The dosage of drug surrounding the implant can be calculated by
considering the concentration of dexamethasone in the nanoparticle
solution and the geometry of the coating. The nanoparticle–
dexamethasone solution was formulated with 5 mg/mL of which
15% was retained in the nanoparticles. Therefore the concentration of
dexamethasone in the nanoparticle solution was 750 µg/mL. This was
mixed into a PEO–water hydrogel at a 1:1 ratio, further diluting the
dexamethasone to 375 µg/mL. However, during the coating process
most of the water will evaporate from the PEO–nanoparticle mixture.
Conservatively assuming that the ﬁnal coating retains 20% moisture,Fig. 7. Impedance progression as a function of time for drug-eluting and non-drug-eluting im
measured at the Peak Resistance Frequency. Legend: the crosses (×) represent the individua
the individual values for drug-eluting microelectrode sites; the dashed gray is the daily ave
eluting sites.the dexamethasone concentration is 300 µg/mL in the coating
material. By considering the 15 nL of coating volume calculated
above, we can conclude that a ﬁnal dosage of 4.5pg of dexamethasone
is present in the immediate vicinity of the microelectrode array.3.2. In vivo impedance comparison
Impedance measurements were performed to determine the
effects of the drug release on the electrical properties of the tissue
reaction. A total of 32 microelectrode sites were measured (i.e. 16
sites for drug-eluting probes and 16 sites for control). For each day the
impedance magnitude at the Peak Resistance Frequency was plotted
for the control and drug-eluting sites. Fig. 7 shows the individual daily
values isolating the impedance magnitude of the tissue reaction only.
The average for each day is demonstrated and a clear trend is
apparent. At the conclusion of the 46 day experiment the ﬁnal average
impedance magnitude for drug-eluting probes is 3.15 MΩ, while the
average for control probes is 4.17 MΩ. This demonstrates an averageplants. The upper graph depicts the evolution of the resistance of the tissue reaction as
l values for the control, non-drug-eluting microelectrodes; the diamonds (♦) represent
rage for all non-drug-eluting sites; the solid gray line is the daily average for all drug-
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drug-eluting devices are used.
3.3. Histological results
Fig. 8 demonstrates a qualitative histological comparison at two
important time points. After one week a substantial increase in the
tissue resistance surrounding the microelectrode is observed, as
conﬁrmed by impedance measurements. It is apparent that the
reaction is limited in comparison to the control device by the ﬁrst
week, and this reduction is maintained by the third week. These
results are comparable to the thorough quantitative analysis of Zhong
and Bellamkonda [11], however such an analysis is beyond the scope
of this paper.
4. Discussion
In comparison to loading a biodegradable material with dexa-
methasone [30], the nanoparticle technique presented here prevents
the rapid diffusion of the drug away from the implantation site [31].
After the coating process, nanoparticles are large enough (800 nm)
that they remain close to the implantation site where the highest
concentration of the drug is required.
The method of release and degradation of the particles is a
combination of oxidation of the PPS core [27] and diffusion. It is not
known for the speciﬁc target cells (i.e. the astrocytes and microglia)
what the drug uptake mechanism in the brain is. However, it is
believed that the uptake method is either through passive processes
(the drug is released into the vicinity of the cell and uptake happens
through diffusion) or the drug-laden nanoparticle is internalized by
the microglia by macropinocytosis or endocytosis [23].
In order to encapsulate hydrophobic molecules such as dexameth-
asone and prevent tissue reaction to the nanoparticles, the materials
must have certain core and surface characteristics. The PPS nanopar-
ticles used here have a hydrophobic core and PEGylated, hydrophillic
surface [23,24,27]. They provide a stable rubbery PPS core in which a
hydrophobic drug can be loaded, which may degrade in an oxidative
environment. The hydrophilic corona of the nanoparticle will prevent
the adhesion of proteins which leads to tissue reaction. These
nanoparticles were shown elsewhere to be non-cytotoxic [27].
The polymer coating does not adversely affect the electrical
characteristics of the electrode sites as was demonstrated in vitro in
a previous study [32]. A coating material was sought that would
rehydrate and fully dissolve after implantation, thus fully exposing
the electrode sites to the neural tissue. Selection of a high molecular
weight of the PEO matrix was important to provide non-instanta-
neous dissolution after re-hydration during implantation. Low
molecular weight PEO or PEG may dissolve during, rather than after,
insertion. However, long-term effects of PEG in the brain are still not
known and can inﬂuence the viability of this technique.
In previous work [12,33], the impedance magnitude at 1 kHz has
been used to determine the extent of tissue reactions. However, this
method yields less insight than Peak Resistance Frequency analysis
because it does not isolate and measure the resistance of the tissue
reaction alone. In fact, measuring at this one frequency does not
provide any insight into the time-changing activity around the
electrode. Only by following the magnitude of the Peak Resistance
Frequency for each individual electrode, and determining the average
daily impedance, can an accurate representation of the increase in the
tissue reaction impedance be possible.
The in vivo experiments demonstrate a decrease by 25% of
impedance magnitude and this result is substantial. For example, it
translates into 25% less current required to stimulate neural tissue.
Electrochemical reactions on the surface of the electrode that can
occur during stimulation can be avoided if the current required for
efﬁcacious stimulation is lower. The decrease in the power required tostimulate has a direct effect on battery life for implantable pulse
generators, and longer battery life is an important clinical need. There
may also be an increase in the signal-to-noise ratio when recording
neural activity. However, in vivo demonstration of improved record-
ing should be the subject of future work.
The impedance measurement methods described in this study can
also be used to evaluate and compare different drug-eluting and
biofunctional coatings. For example, there have been reports of
nanoscale laminin coatings [34] and bioactive coatings [35,36]. These
coatings could be applied to the devices presented here and a
quantitative comparison of the tissue reaction could be performed.
The evaluation and comparison of different dosages or release kinetics
can also be performed using this technique. To control release
kinetics, coatings may be a combination of several layers with
different drug concentrations in order to take advantage of different
release kinetics as demonstrated elsewhere [8]. For example, the
outer-most layer of the coatingmay contain the highest concentration
of nanoparticles in order to provide a high initial dosage or “burst”,
while subsequent layers will slowly reduce in drug concentration.
5. Conclusion
We have described a method to synthesize nanoparticles with a
hydrophobic core made of poly(propylene sulﬁde) and a hydrophilic
corona of poly(ethylene glycol). The nanoparticles were loaded with
dexamethasone, a hydrophobic drug, and incorporated it into a high
molecular weight poly(ethylene oxide) matrix for use as an anti-
inﬂammatory coating on microfabricated polymer neuroprostheses.
The nanoparticles protect the drug from degradation, and ensure its
controlled release with ﬁrst order kinetics over 9 days.
An overall reduction in post-implantation impedance for micro-
electrode sites that were coated with the dexamethasone-eluting
material was shown. An average reduction of 25% in impedance at the
Peak Resistance Frequency was observed in comparison to control
devices, demonstrating that the tissue reaction was reduced and the
drug-eluting material was effective.
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